CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.
.
For our Members, please find below the list of our latest Model Portfolio changes.
Our Algo Model has now closed out one of the best performing investments. After holding Nextdc for 2054 days, the realised gain was 412.93%.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
For our Members, please find below the list of our latest Model Portfolio changes.
We add IAG to our “high risk” recovery basket, which also includes CIM & A2M.
We expect IAG to see improved earnings into FY22 & FY23. It’s likely we’re nearing the inflection point, where investors begin pricing in the anticipated recovery.
Buy IAG with stops below $4.60
Ampol has reported its financials for the 12 months ending 31 December 2020, with full year earnings of $401 million. Earnings were down from $607 million in the year prior.
1Q21 EBIT was A$150mn, but included an A$18mn FX gain.
ALU:ASX is under Algo Engine buy conditions and has now rallied 20% from the recent low. Our interest in the business has increased and the stock is now under review.
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
For our Members, please find below the list of our latest Model Portfolio changes.
Level 17 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453
Or start a free thirty day trial for our full service, which includes our ASX Research.